Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crizotinib

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

Roche announces two-year data confirming Vabysmo improves neovascular age-related macular degeneration

The data showed, after two years, that 60% of patients treated with Vabysmo could be treated every four months, compared with 45% in year one

- PMLiVE

GSK creates new consumer healthcare business, Haleon

Haleon, whose brand portfolio will include Sensodyne toothpaste and Panadol painkillers, is the combination of the consumer health businesses of GSK and Pfizer

- PMLiVE

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

If approved, this could be the first such antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma

- PMLiVE

Pfizer’s Paxlovid given FDA permission to be prescribed by US pharmacists

Under the Emergency Use Authorisation revision, pharmacists will be able to prescribe the COVID-19 treatment to patients, providing they meet certain conditions

- PMLiVE

Pfizer announces commitment to achieve Net-Zero Standard by 2040

The company hopes to achieve the net-zero target ten years earlier than the expectations of the Net-Zero Standard

- PMLiVE

Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government

The companies will supply 105 million doses, which may include adult Omicron-adapted COVID-19 vaccines, subject to FDA authorisation

- PMLiVE

Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine

Preliminary laboratory studies show both vaccines neutralise Omicron BA.4 and BA.5

- PMLiVE

Enanta takes legal action against Pfizer over Paxlovid patent infringement

The lawsuit claims the oral COVID-19 antiviral infringes on Enanta’s 11,358,953 patent

- PMLiVE

Pfizer donates $5m in Russian profits to humanitarian causes amid war in Ukraine

The donation will go to eight global and local NGOs to support humanitarian relief and response efforts

- PMLiVE

Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy

Around 200 million women suffer from endometriosis worldwide and it can take between four to eleven years to get a diagnosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links